Fig. 1From: Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, RussiaDistribution of responses to etanercept in different JIA categories within 12 months after beginning treatmentBack to article page